Latest Trials Latest NewsFAQ

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients

Phase 1

Completed

Conditions: Metastatic Renal Cell Carcinoma
Kidney Cancer

First Posted Date: 2007-01-12

Last Posted Date: 2008-11-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT00421512

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, New York, United States

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Phase 1

Completed

Conditions: Small Intestine Cancer
Leukemia
Lymphoma

Interventions: Drug: clofarabine

First Posted Date: 2006-12-28

Last Posted Date: 2022-05-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 29

Registration Number: NCT00416351

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: bevacizumab
Drug: dexamethasone
Drug: floxuridine
Genetic: protein expression analysis
Other: flow cytometry
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: immunologic technique
Other: laboratory biomarker analysis
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2006-12-13

Last Posted Date: 2024-12-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT00410956

Locations: 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Depression Screening in Patients With Lung Cancer

Not Applicable

Completed

Conditions: Depression
Lung Cancer

Interventions: Other: counseling intervention
Other: screening questionnaire administration
Other: study of socioeconomic and demographic variables
Procedure: psychosocial assessment and care

First Posted Date: 2006-11-28

Last Posted Date: 2013-05-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 241

Registration Number: NCT00404365

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States

Trial of Acupuncture for Reduction of Post-Colectomy Ileus

Phase 2

Completed

Conditions: Colon Cancer
Postoperative Ileus
Postoperative Nausea and Vomiting
Pain, Postoperative

Interventions: Other: Sham Acupuncture
Other: Acupuncture

First Posted Date: 2006-11-23

Last Posted Date: 2015-10-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 90

Registration Number: NCT00402961

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, New York, United States

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Phase 1

Completed

Conditions: Leukemia
Lung Cancer
Malignant Mesothelioma
Primary Peritoneal Cavity Cancer
Myelodysplastic Syndromes

Interventions: Biological: WT-1 analog peptide vaccine
Biological: incomplete Freund's adjuvant
Biological: sargramostim
Genetic: polymerase chain reaction
Other: flow cytometry
Other: immunoenzyme technique

First Posted Date: 2006-11-10

Last Posted Date: 2016-03-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT00398138

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Phase 1

Completed

Conditions: Intraocular Melanoma
Melanoma (Skin)

Interventions: Biological: mouse gp100 plasmid DNA vaccine
Device: The Dermal PowderMed® devices
Other: intramuscularly (IM injection)

First Posted Date: 2006-11-10

Last Posted Date: 2017-03-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 35

Registration Number: NCT00398073

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Biological: cetuximab
Drug: cisplatin
Drug: irinotecan hydrochloride
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: biopsy

First Posted Date: 2006-11-10

Last Posted Date: 2015-11-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT00397904

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Phase 2

Completed

Conditions: Transitional Cell Cancer of the Renal Pelvis and Ureter
Bladder Cancer
Urethral Cancer

Interventions: Drug: sunitinib malate

First Posted Date: 2006-11-09

Last Posted Date: 2016-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 78

Registration Number: NCT00397488

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Biological: MAB HER 2 (HERCEPTIN)

First Posted Date: 2006-10-29

Last Posted Date: 2024-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT00393783

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy